The ability to disrupt biofilms formed by a variety of different Gram-negative and Gram-positive bacteria suggests that, like the previously characterized glycoside hydrolases DspB [31–33], PelA [56, 57], PslG [30, 56], Sph3 [29, 57], NghA [58], and PssZ [27], PgaB may have therapeutic potential for treatment of a broad range of infections caused by PNAG-producing bacteria such as E. coli [34], Staphylococcus spp. Here, SPTA1 is linked to infection.